X-Band TDS Project

Based on the success of the X-Band Transverse Deflecting Structure (TDS) diagnostic at LCLS*, a collaboration between DESY, PSI and CERN has formed with the aim of developing and building an advanced modular X-Band TDS system. The designed TDS has the new feature of providing variable polarization of the deflecting field**. The possibility of changing the orientation of the streaking field of the TDS to an arbitrary azimuthal angle allows for 3D characterization of the phase space using tomographic methods***. Moreover the complete 6D characterization of the beam phase space is possible by combining this technique with quadrupole scans and a dipole spectrometer. As this new cavity design requires very high manufacturing precision to guarantee highest azimuthal symmetry of the structure to avoid the deterioration of the polarization of the streaking field, the high precision tuning-free assembly procedures developed at PSI for the SwissFEL C-band accelerating structures will be used for the manufacturing****. The high-power rf system is based on the CERN-based X-band test stands. We summarize in this work the status of the projects and its main technical parameters

An international expanded-access programme of Everolimus : Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

BACKGROUND AND OBJECTIVES: The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. The REACT (RAD001 Expanded Access Clinical Trial in RCC) study was initiated to address an unmet medical need by providing everolimus prior to commercial availability, and also to further assess the safety and efficacy of everolimus in patients with VEGFr-TKI-refractory mRCC. PATIENTS AND METHODS: REACT (Clinicaltrials.gov: NCT00655252) was a global, open-label, expanded-access programme in patients with mRCC who were intolerant of, or who had progressed on or after stopping treatment with, any available VEGFr-TKI therapy. Patients received everolimus 10mg once daily, with dose and schedule modifications allowed for toxicity. Patients were closely monitored for the development of serious and grades 3/4 adverse events (AEs). Response was assessed by RECIST every 3months for the first year and every 6months thereafter. RESULTS: A total of 1367 patients were enroled. Safety findings and tumour responses were consistent with those observed in RECORD-1, with no new safety issues identified. The most commonly reported serious AEs were dyspnoea (5.0%), pneumonia (4.7%) and anaemia (4.1%), and the most commonly reported grades 3/4 AEs were anaemia (13.4%), fatigue (6.7%) and dyspnoea (6.5%). Best overall response was stable disease in 51.6% and partial response in 1.7% of patients. Median everolimus treatment duration was 14weeks. CONCLUSION: Everolimus is well tolerated in patients with mRCC and demonstrates a favourable risk-benefit ratio